Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026)

Protalix BioTherapeutics has reported Common Equity for 17 years, with the latest figure at $71.4 million in Q2 2026.

• On a quarterly basis, Common Equity rose 43.09% year-over-year to $71.4 million in Q2 2026; TTM through Jun 2026 was $71.4 million, a 43.09% increase from a year earlier, with the FY2025 full-year figure at $48.2 million, up 11.62% from the prior year.
• Common Equity was $71.4 million for Q2 2026 at Protalix BioTherapeutics, up from $67.2 million in the prior quarter.
• The five-year high for Common Equity was $120.0 million in Q2 2022, with the low at -$11.5 million in Q3 2022.
• Average Common Equity over 5 years is $37.3 million, with a median of $38.6 million recorded in 2023.
• The largest YoY upside for Common Equity was 3024.19% in 2022 against a maximum downside of 5505.63% in 2022.
• Over 5 years, Common Equity stood at -$10.6 million in 2022, then jumped by 415.5% to $33.6 million in 2023, then gained by 28.72% to $43.2 million in 2024, then advanced by 11.62% to $48.2 million in 2025, then jumped by 48.05% to $71.4 million in 2026.
• The last three Common Equity figures came in at $71.4 million (Q2 2026), $67.2 million (Q1 2026), and $48.2 million (Q4 2025), per Business Quant data.